In This Article:
As global markets navigate a landscape marked by political developments and economic shifts, U.S. stocks have surged to record highs, fueled by optimism over trade policies and advancements in artificial intelligence. Amidst this buoyant market environment, identifying stocks that may be undervalued can offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Alltop Technology (TPEX:3526) | NT$264.50 | NT$526.72 | 49.8% |
| Berkshire Hills Bancorp (NYSE:BHLB) | US$28.32 | US$56.60 | 50% |
| Shenzhen Yinghe Technology (SZSE:300457) | CN¥18.80 | CN¥37.54 | 49.9% |
| World Fitness Services (TWSE:2762) | NT$92.70 | NT$184.63 | 49.8% |
| Vertiseit (OM:VERT B) | SEK50.20 | SEK99.93 | 49.8% |
| Fudo Tetra (TSE:1813) | ¥2153.00 | ¥4301.30 | 49.9% |
| Greenworks (Jiangsu) (SZSE:301260) | CN¥13.95 | CN¥27.81 | 49.8% |
| Shinko Electric Industries (TSE:6967) | ¥5854.00 | ¥11678.68 | 49.9% |
| Jiangsu Chuanzhiboke Education Technology (SZSE:003032) | CN¥9.10 | CN¥18.19 | 50% |
| Tenable Holdings (NasdaqGS:TENB) | US$43.39 | US$86.65 | 49.9% |
Here we highlight a subset of our preferred stocks from the screener.
Tikehau Capital
Overview: Tikehau Capital is an alternative asset management group with €46.1 billion in assets under management and a market capitalization of approximately €3.72 billion.
Operations: The company's revenue segments include €173.11 million from investment activities and €322.94 million from asset management activities.
Estimated Discount To Fair Value: 42.4%
Tikehau Capital is trading at €21.65, significantly below its estimated fair value of €37.59, highlighting potential undervaluation based on cash flows. Despite a dividend yield of 3.46% not being well covered by free cash flows, the company shows strong growth prospects with earnings expected to rise by 35.9% annually, outpacing the French market's forecasted growth rate of 12%. However, debt coverage by operating cash flow remains a concern for investors.
BioArctic
Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK19.23 billion.
Operations: The company's revenue primarily comes from its biotechnology segment, amounting to SEK167.14 million.